Related Experiment Video
Updated: Aug 12, 2026
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Tumour surveillance: missing peptides and MHC molecules
1Tumour Immunology Laboratory, Epstein-Barr Virus Unit, Queensland Institute of Medical Research, Bancroft Centre, Herston, Australia. rajivK@qimr.edu.au
Abstract:
Immunotherapy involving CTL is an attractive alternative for treatment of various malignancies. One of the approaches currently being explored for immune targeting of human cancers involves potentiation of immunogenicity of malignant cells by gene transduction. This strategy is undoubtedly influenced by the ability of the malignant cells to endogenously process and present target epitopes on their cell surface for immune recognition by CTL. However, there is increasing evidence to suggest that a large proportion of human cancers escape CTL-mediated immune surveillance by selectively down-regulating the expression of MHC class I molecules and peptide transporter genes. Understanding and molecular analysis of these immunologically relevant genetic defects in tumours is very important before translating preclinical studies of immunotherapy to rational clinical trials. Careful consideration of these potential limitations may lead to the development of novel immunotherapeutic strategies and, potentially, prevention of tumour progression or development.
Insights
Cancer immunotherapy using cytotoxic T-lymphocytes (CTL) shows promise, but many cancers evade detection. Understanding genetic defects in tumor cells is crucial for developing effective cancer treatments.
Area of Science:
- Oncology
- Immunology
- Cancer Genetics
Background:
- Immunotherapy utilizing cytotoxic T-lymphocytes (CTL) is a promising strategy for treating various cancers.
- Enhancing cancer cell immunogenicity through gene transduction is being explored for immune targeting.
- Tumor cells' ability to process and present target epitopes is key for CTL recognition.
Purpose of the Study:
- To analyze the molecular mechanisms by which tumors escape CTL-mediated immune surveillance.
- To understand the role of MHC class I and peptide transporter gene downregulation in immune evasion.
- To inform the development of rational clinical immunotherapy trials.
Main Methods:
- Analysis of genetic defects in tumor cells related to immune evasion.
- Molecular investigation of MHC class I and peptide transporter gene expression in malignancies.
- Review of preclinical immunotherapy studies and their clinical translation challenges.
Main Results:
- A significant proportion of human cancers down-regulate MHC class I molecules and peptide transporter genes.
- These genetic defects allow tumors to escape CTL-mediated immune surveillance.
- Understanding these defects is critical for successful immunotherapy.
Conclusions:
- Identifying and analyzing tumor-specific genetic defects is essential before clinical immunotherapy trials.
- Addressing these immune evasion mechanisms can lead to novel immunotherapeutic strategies.
- This research may aid in preventing tumor progression and development.
More Related Videos
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
09:32Immunopeptidomics: Isolation of Mouse and Human MHC Class I- and II-Associated Peptides for Mass Spectrometry Analysis
Published on: October 15, 2021